Nkarta (NKTX) EBIT Margin (2019)
Nkarta (NKTX) posted quarterly EBIT Margin of 1534805.19% for Q3 2019, up 858.4% quarter-over-quarter from 202375.3% in Q2 2019.
Nkarta (NKTX) EBIT Margin (2019) Analysis & Trends
Nkarta's EBIT Margin history runs 1 years deep, the most recent figure standing at 1534805.19% for Q3 2019.
- In Q3 2019, EBIT Margin changed N/A year-over-year to 1534805.19%; the TTM figure through Dec 2020 stood at 13378441.56% (changed N/A YoY), while the FY2019 annual figure was 19433.91%, changed N/A from the prior year.
- EBIT Margin for Q3 2019 stood at 1534805.19%, up from 202375.3% in the prior quarter.
- The five-year high for EBIT Margin was 1534805.19% in Q3 2019, with the low at 202375.3% in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Nkarta | 185.49 Mn | 185.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 1,534,805.19% |
| Jun 30, 2019 | -202,375.30% |